Shweta Singh, S.K. Pandey


INTRODUCTION-Lamotrigine (LTG) is an anti-epileptic drug (AED) and also used as a neuromodulator, in mood
disorders.Metabolism is primarily achieved by competitive glucuronic acid conjugation. The principal product is an inactive
lamotrigine-2-N-glucuronide conjugate, found predominantly in urine and to a lesser extent in feces. Recently, malformations
have been reported in human foetuses, whose mothers were treated with LTG. However, it is not been possible to establish a
recognizable pattern of malformations in the kidneys of human foetuses treated with LTG, therefore the lower animal has been
used as experimental model for the present study.
OBJECTIVE- The objective of this study is to find out the microscopic changes in the kidney of the growing embryo of mice treated
with LTG in both early and late phase of gestation.
MATERIAL AND METHODS The pregnant mice were divided into two experimental groups i.e. early and late, each with two
subgroups i.e. control group (treated with intra peritoneal injection of normal saline on Day 4 and Day 9 of gestation) and treated
th th group (treated with intraperitoneal injection of LTG ,150mg/kg body weight on 4 day and 9 Day of gestation. Fetuses were
th collected on day 18 of gestation and after fixation the kidneys were dissected out and processed for histological examination.
RESULT - The results of this study indicate that LTG administered intra peritoneally at high doses causes shrinkage of cortex and
medulla and degenerated glomeruli, shrinkage of glomeruli and appearance of edematous spaces between the ducts.
CONCLUSION- In the present study histopathological changes were seen to be caused by LTG in the kidney of developing mice.


Teratogenic, Lamotrigine, Microscopic, Kidney, Developing Mice.

Full Text:



GlaxoSmithKline: Lamictal (lamotrigine) prescribing information. Research Triangle Park, NC, GlaxoSmithKline, May 2007.

.Bowden CL, Calabrese JR, Sachs G, et al: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60:392–400, 2003.

Ohman I, Vitols S, Tomson T: Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 41:709–713, 2000

Pennell PB, Newport DJ, Stowe ZN, et al: The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 62:292–295, 2004.

Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 338:1128-37,1998.

Marchi NS, Azoubel R, Tognola WA. Teratogenic effects of lamotrigine on rat fetal brain: a morphometric study. ArqNeuropsiquiatr 59:362-4,2001

Singh S and Pandey S.K. Adverse macroscopic changes in developing mice treated with Lamotrigine on early and late phase of gestation. International Journal Of Current Advanced Research Vol.7, issue,2(G),pp.10104-10107, February ,2018.

Padmanabhan R, Abdulrazzaq YM, Bastaki SM, Shafiullah M, Chandranath SI. Experimental studies on reproductive toxicologic effects of lamotrigine in mice. Birth Defects Res B Dev ReprodToxicol 68:428-38,2003.

Iqbal MM, Gundlapalli SP, Ryan WG, Ryals T, Passman TE. Effect of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants. South Med J 94:304-22,2001

Rahmani F, Delaram M, Forouzandeh N: The teratogenic effects of Lamotrigine on mouse fetus. Journal ofReproduction and Infertility,7(1):45-52,2006.

Wilson JG. Environment and birth defects. New York: Academic Press.1973

Wilson JG. Current status of teratology. The handbook of teratology. 2.Ed. New York: Plenum Press 47-74,1979.

Cunnington M,,Ferber.S.Effect of Dose on the Frequency of Major Birth Defects Following Fetal Exposure to Lamotrigine Monotherapy in an International Observational Study. Epilepsia,48(6):1041-1222,2007.


  • There are currently no refbacks.